BofA raises Lam Research stock price target on margin gains By Investing.com

BofA raised Lam Research’s price target to $330 from $285 while keeping a Buy rating after the company beat quarterly sales and EPS expectations by 2% and 8%, respectively. June-quarter guidance was also 9% and 14% above consensus for sales and earnings, and gross margin improved about 100 bps to 50.5%. BofA boosted its CY2026 and CY2027 EPS estimates by 12% and 33% to $9.21 and $10.31, citing share gains in etch and deposition.

Analysis

The market is starting to re-rate LRCX less as a cyclical tool maker and more as a structural beneficiary of memory intensity and process complexity. The important second-order effect is that stronger long-dated spending commitments from memory customers reduce the classic capex whiplash, which should support a higher trough multiple for the entire etch/deposition ecosystem, not just Lam. That said, at this valuation the stock is now discounting a multi-year execution runway; incremental upside likely requires not just beat-and-raise quarters, but evidence that share gains are durable against Applied and Tokyo Electron in the next 2-3 customer procurement cycles.

The near-term risk is that the stock has already moved far ahead of fundamentals, so any digestion in wafer fab equipment demand or a pause in order timing could trigger multiple compression even if revenue remains healthy. The move from 41x to 36x forward earnings in the target framework is still aggressive for a name that is now trading like a quality compounder rather than a cyclical. The key catalyst path is over the next 2-4 quarters: if customer confidence in 2028 spending translates into actual non-cancelable orders, the market can sustain the premium; if it stays at the discussion stage, the multiple becomes vulnerable.

The contrarian take is that the market may be underestimating how much of the good news is already reflected in consensus revisions. A 12%/33% EPS step-up is sizable, but if estimates for 2027 are still moving this fast, the issue becomes less fundamental strength and more whether the market has already pulled forward too much of 2026-2027 upside. In other words, the best risk/reward may have shifted from outright long equity to expressing bullishness through pullbacks, call spreads, or relative value versus peers that are more exposed to a softer leading-edge node mix.

Key Decisions for Investors

• Trim/hedge existing LRCX longs into strength; the stock is trading like a premium growth compounder, so upside from here is likely lower than downside if WFE sentiment cools over the next 1-2 quarters.
• For new money, buy LRCX only on a 5-8% pullback or use a 3-6 month call spread to express upside with defined premium risk; avoid outright chasing after the recent re-rate.
• Pair trade: long LRCX / short a more memory-exposed equipment peer over the next 6 months if you want to isolate Lam’s etch/deposition share gains, but size modestly because the whole group is being de-risked by long-term customer commitments.
• Use a relative-value hedge: long LRCX against short a broader semicap basket if WFE remains firm, to capture execution alpha while limiting beta to an industry multiple reset.
• Watch for any order-book or guidance stumble over the next earnings cycle; if bookings fail to confirm 2028 optimism, expect 15-20% downside from multiple compression even without a fundamentals miss.